TISSUE REGENIX
Tissue Regenix commercializes innovative technologies in regenerative medicine. The underpinning science was developed over the last decade in the world-leading Institute for Medical and Biological Engineering at the University of Leeds by Professors John Fisher and Eileen Ingham. Tissue Regenix was founded in May 2006, to commercialize innovative technologies in regenerative medicine.
TISSUE REGENIX
Industry:
Health Care Health Diagnostics Medical Device
Founded:
2006-05-01
Address:
York, York, United Kingdom
Country:
United Kingdom
Website Url:
http://www.tissueregenix.com
Total Employee:
51+
Status:
Active
Contact:
+44 1904 567609
Email Addresses:
[email protected]
Total Funding:
15.29 M GBP
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Domain Not Resolving Apple Mobile Web Clips Icon Google Analytics Google Maps Google Universal Analytics Apache Google Maps API PHP
Similar Organizations
Flatechs
Medtech company specializing in safety solution in critical care medicine.
Joint Academy
Joint Academy connects patients with licensed physical therapists to deliver online treatments for chronic joint and back pain.
Seno Medical Instruments
Seno Medical is commercialization efforts in opto-acoustic imaging of breast cancer.
Trice Medical
Trice Medical specializes in providing solutions for orthopedic diagnostics.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2017-07-21 | CellRight Technologies | CellRight Technologies acquired by Tissue Regenix | 30 M USD |
Investors List
Aquarius Equity Partners
Aquarius Equity Partners investment in Venture Round - Tissue Regenix
White Rose Technology Seedcorn Fund
White Rose Technology Seedcorn Fund investment in Venture Round - Tissue Regenix
IP Group
IP Group investment in Venture Round - Tissue Regenix
Official Site Inspections
http://www.tissueregenix.com
- Host name: 51.104.28.64
- IP address: 51.104.28.64
- Location: London United Kingdom
- Latitude: 51.5164
- Longitude: -0.093
- Timezone: Europe/London
- Postal: EC2V
More informations about "Tissue Regenix"
Tissue Regenix - Crunchbase Company Profile & Funding
Tissue Regenix commercializes innovative technologies in regenerative medicine. The underpinning science was developed over the last decade in the world-leading Institute for Medical and Biological Engineering at the University of …See details»
Business overview - Tissue Regenix
TISSUE REGENIX GROUP is a pioneering, international medical technology company, focusing on the development of regenerative products utilising our two platform technologies, dCELL ®, …See details»
Our story - Tissue Regenix
Spun out of the University of Leeds in 2006, Tissue Regenix commercialise research undertaken by our higher education and research partners around the world.See details»
Tissue Regenix Group Information - RocketReach
Tissueregenix.com; 3 678455XXXX; 678428XXXX; 678428XXXX; Rebekah Taylor Head of Quality and Regulatory Affairs at Tissue Regenix Group Leeds, Leeds, United Kingdom View. 2 …See details»
Tissue Regenix Group Company Profile | Management and
[email protected]: 6: first: [email protected]: 7: last: [email protected]: Your Questions, Our Answers Get Free Access to Tissue Regenix …See details»
Tissue Regenix Group - Overview, News & Similar companies
Nov 17, 2020 Explore Complete Organization Structure. Is Tissue Regenix Group your ideal customer? Let us give you the heads up on whether it's a good time to reach out. Last 7 days. …See details»
Tissue Regenix Group - LinkedIn
Tissue Regenix Group | 3,992 followers on LinkedIn. Tissue Regenix is a leading medical devices company in the field of regenerative medicine. Tissue Regenix was formed in 2006 when it was spun ...See details»
Company Tissue Regenix Group plc - MarketScreener.com
Tissue Regenix Group plc: Company profile, business summary, shareholders, managers, financial ratings, industry, sector and market information | London S.E.: TRX ...See details»
Home - Tissue Regenix
Tissue Regenix Group. Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative productsSee details»
Tissue Regenix Group - Craft
Oct 29, 2024 Tissue Regenix Group has 5 employees across 3 locations and $29.49 m in annual revenue in FY 2023. See insights on Tissue Regenix Group including office locations, …See details»
Business model - Tissue Regenix
In order to continue to create value for our stakeholders, we invest in the Group’s key resources. For example, we develop our people and our IP, as well as furthering our manufacturing …See details»
Walbrook | Tissue Regenix Group plc
Www.tissueregenix.com. Sector. Pharmaceuticals & Biotechnology (Biotechnology) Description. Tissue Regenix Group plc (AIM: TRX) is a pioneering, international medical technology …See details»
Our strategy - Tissue Regenix
Accelerate US market penetration Description. The US is the largest healthcare market in the world and where we see the greatest opportunity. We intend to leverage our platform …See details»
Tissue Regenix Group Management Team | Org Chart
Tissueregenix.com; View Similar People. Related Companies EGYM | United Kingdom. 424 $75.2m Firesprite. 220 $16.1m Exscientia. 462 $35.6m Ithaca Energy. 651 $267.5m Rencol …See details»
Tissue Regenix - VentureRadar
Similar Companies: AVACTA GROUP PLC United Kingdom Publicly Traded Avacta is developing innovative chemical and biological detection technology for the healthcare, defence, …See details»
Business model - Tissue Regenix
Gentle soft tissue decellularisation process, removing DNA and cellular material to reduce risk of rejection. The dCELL ® process involves the creation of biological scaffolds which are …See details»
Our technology - Tissue Regenix
Tissue Regenix Group is a pioneering, international medical technology company, focusing on the development of regenerative products.See details»
Regenerative medicine - Tissue Regenix
Regenerative medicine has the ability to alleviate some of this economic pressure as it can provide patients with longer lasting solutions, reducing the need for immunosuppressant …See details»